CN113750068A - 一种托拉塞米片及其制备方法 - Google Patents
一种托拉塞米片及其制备方法 Download PDFInfo
- Publication number
- CN113750068A CN113750068A CN202111264676.8A CN202111264676A CN113750068A CN 113750068 A CN113750068 A CN 113750068A CN 202111264676 A CN202111264676 A CN 202111264676A CN 113750068 A CN113750068 A CN 113750068A
- Authority
- CN
- China
- Prior art keywords
- torasemide
- parts
- magnesium stearate
- tablet
- tabletting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 229960005461 torasemide Drugs 0.000 title claims abstract description 86
- 238000002360 preparation method Methods 0.000 title abstract description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 50
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 25
- 238000002156 mixing Methods 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 23
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 22
- 229930195725 Mannitol Natural products 0.000 claims abstract description 22
- 239000000594 mannitol Substances 0.000 claims abstract description 22
- 235000010355 mannitol Nutrition 0.000 claims abstract description 22
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 21
- 239000008101 lactose Substances 0.000 claims abstract description 21
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 18
- 239000013078 crystal Substances 0.000 claims description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 4
- 230000001050 lubricating effect Effects 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 230000009467 reduction Effects 0.000 abstract description 6
- 239000000314 lubricant Substances 0.000 abstract description 5
- 238000005265 energy consumption Methods 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 230000027939 micturition Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 10
- 238000007873 sieving Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 239000008119 colloidal silica Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001882 diuretic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 4
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960002478 aldosterone Drugs 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002171 loop diuretic Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002337 osmotic diuretic agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种托拉塞米片处方原料组分包括:托拉塞米1~20份,甘露醇50~250份,乳糖5~100份,胶态二氧化硅0.25~4份,硬脂酸镁0.25~2.5份;本发明的托拉塞米片经过混料和压片的制备方法而得,生产步骤简洁、耗能少,成本低;通过选择较小粒径的片状晶体形状的硬脂酸镁作为润滑剂,纳米硅溶胶式胶态二氧化硅作为助流剂,得到的托拉塞米片药品稳定性好;避免出现常规制剂峰谷现象,实现零级释放、平稳溶出、降压平稳,避免尿急尴尬,降低毒副作用,患者口服后能充分吸收。
Description
技术领域
本发明涉及托拉塞米药品制备技术领域,特别涉及一种托拉塞米片组分以及该托拉塞米片的制备方法。
背景技术
利尿药根据药物作用机制特点主要分为:渗透性利尿药、碳酸酐酶抑制药、袢利尿药、噻嗪类利尿药、保钾利尿药。托拉塞米属于吡啶酰胺脲类高效髓袢利尿剂,托拉塞米适应证广,利尿作用迅速强大且持久,不良反应发生率低,为现今临床上常用的一类高效利尿剂。广泛用于充血性心力衰竭、肾衰竭和肾病综合征、肝硬化腹水等疾病所致水肿、高血压等疾病的治疗。其作用于髓袢升支粗段,干扰管腔细胞膜的Na+-K+-2Cl-同向转动体系,抑制Cl-和Na+的重吸收,使管液NaCl的浓度增高,渗透压增大,肾髓质间液的NaCl减少,渗透压梯度降低,从而干扰尿的浓缩过程,使尿Na+、Cl-和水的排泄增加,发挥利尿作用;同时抑制前列腺素分解酶活性,增加血浆中前列腺素E(PGE2)和前列环素(PGI2)浓度,竞争拮抗血栓素A2(TXA2)和TXB2的缩血管作用;此外,托拉塞米还可抑制醛固酮分泌、抑制肾小管细胞胞浆中醛固酮与受体结合、降低醛固酮活性,具有保钠排钾的作用。
托拉塞米口服生物利用度高,口服和非肠道给药疗效几乎相同。药理和临床研究表明,本品既具有氢氯噻嗪类利尿剂作用时间长的特点,又具有高效利尿作用,所以既可用于治疗严重水肿类病症,又适合于原发性高血压的长期治疗。在低剂量口服托拉塞米时无副作用,大剂量口服时未出现重要的不良反应,患者机体耐受性好。通过肝肾双通道代谢,80%经肝脏代谢,20%以原形经肾脏排泄,有效减轻了肾脏负担和药物蓄积。其独特的醛固酮拮抗作用由于本品仅有少量治疗量经过肾清除,故对肾衰患者用药同样安全,无积累作用,临床应用较为广泛;但是现有工艺显示,该产品为湿法制粒工艺,工艺步骤包括制粒、干燥、过筛、混合、压片,所需生产设备为湿法制粒机、烘箱或流化床、混合机、压片机,生产步骤较多、能耗大,生产成本高;且在高温高湿热条件下易降解产生杂质,影响产品稳定性。为此,本发明提供一种托拉塞米片组分及该托拉塞米片的制备方法。
发明内容
本发明的目的在于克服现有技术的缺陷,提供一种托拉塞米片的制备方法,通过选取合适的处方原料混合后直接压片,不仅减少生产步骤,去掉湿法制粒、烘干、整粒而降低能耗,还避免药品在高温等严苛条件下发生的降解风险,提高产品稳定性。
为了实现上述目的,本发明提供的一种托拉塞米片,处方原料组分包括:托拉塞米1~20份,甘露醇50~250份,乳糖5~100份,胶态二氧化硅0.25~4份,硬脂酸镁0.25~2.5份;该托拉塞米片主药为托拉塞米粉末,甘露醇、乳糖为填充剂,胶态二氧化硅为助流剂,硬脂酸镁为润滑剂。
为了实现上述目的,本发明还提供制备一种托拉塞米片的制备方法,具体包括以下步骤:
S1处方原料处理,将托拉塞米粗品过经过粉碎和筛选处理,保证所述托拉塞米的粉末平均粒径D90≦150μm;
S2填充剂混合,将甘露醇和乳糖分别经过30~40目筛子后,与托拉塞米粉末在混料机中混合20min~30min,搅拌速度150~250rpm;
S3助留处理,将胶态二氧化硅加入混料机中混合10min~20min,搅拌速度100~200rpm;
S4润滑处理,将平均粒径为3.5~7μm的片状晶体形状的硬脂酸镁加入混料机中混合10min~20min,搅拌速度80~120rpm,控制处方原料温度30~32℃;
S5制片,将混合后的处方原料转入压片模具进行制片得到托拉塞米片;控制压片温度28~30℃,压片时间30~60s。
优选的,所述胶态二氧化硅为纳米硅溶胶,平均粒径为50~150nm。
相比于现有技术,本发明具有如下有益效果:
1、本发明提供的托拉塞米片经过混料和压片的制备方法而得,生产步骤简洁、耗能少,成本低,能按发明制备的样品,含量、溶出均与某市售制剂一致,不同条件下的稳定性优于该制剂。该托拉塞米片,避免出现常规制剂峰谷现象,实现零级释放、平稳溶出、降压平稳,避免尿急尴尬,降低毒副作用,患者口服后能充分吸收;本发明提供的片剂稳定性及用药顺应性良好,生产工艺简单,成本较低,易于工业化生产。
2、由于处方原料托拉塞米易形成颗粒较大的结晶、以及结晶困难造成的技术缺陷,本发明通过选择性控制托拉塞米粉末的粒径为D90≦150μm,从而在制备过程中分散均匀,在药物服用时易于溶解,且持续平稳溶出,提高药品的有效性和持续作用时间。
3、采用纳米硅溶胶式胶态二氧化硅作为助流剂,起吸附分散剂作用,以增加黏性,以免成型过程中沉淀,降低释放速率;其比表面积大,分散粉料时候比较均匀,并且具有一定的载体作用,增加药物稳定性,避免出现常规制剂峰谷现象,实现零级释放、平稳溶出、降压平稳。
4、选择较小粒径的片状晶体形状的硬脂酸镁作为润滑剂,并且在相对较低的温度下进行混合处理,使其片状晶体结构层叠在混合的过程中被分开,均匀覆盖于托拉塞米单个颗粒或表面,有效改善托拉塞米平稳溶出,避免制剂溶出峰谷现象,实现零级释放平稳降压。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明作进一步的详细说明,以使本领域技术人员能够充分理解本发明的技术内容。应理解,以下实施例用于对本发明进行进一步说明,不能理解为对本发明保护范围的限制,本领域的技术人员根据本发明的上述内容作出的一些非本质的改进和调整均属于本发明的保护范围。下述示例具体的工艺参数等也仅是合适范围中的一个示例,即本领域技术人员可以通过本文的说明做合适的范围内选择,而并非要限定于下文示例的具体数值。
本发明提供制备一种托拉塞米片的制备方法,具体包括以下步骤:
1、处方原料处理,将托拉塞米1~20份粗品过经过粉碎和筛选处理,保证托拉塞米粉末的粒径D90≦150μm;
2填充剂混合,将甘露醇50~250份和乳糖5~100份分别经过30~40目筛子后,与托拉塞米粉末在混料机中混合20min~30min,搅拌速度150~250rpm;
3助留处理,将平均粒径为50~150nm纳米硅溶胶的胶态二氧化硅0.25~4份加入混料机中混合10min~20min,搅拌速度100~200rpm;
4润滑处理,将平均粒径为3.5~7μm的片状晶体形状的硬脂酸镁0.25~2.5份加入混料机中混合10min~20min,搅拌速度80~120rpm,控制处方原料温度30~32℃;
5制片,将混合后的处方原料转入压片模具,控制压片温度28~30℃,压片时间30~60s进行制片得到托拉塞米片。得到的托拉塞米片,避免出现常规制剂峰谷现象,实现零级释放、平稳溶出、降压平稳,避免尿急尴尬,降低毒副作用,患者口服后能充分吸收;本发明提供的片剂稳定性及用药顺应性良好,生产工艺简单,成本较低,易于工业化生产。
实施例1:
该托拉塞米片的制备方法,主药为托拉塞米,甘露醇、玉米淀粉为填充剂,胶态二氧化硅为助流剂,硬脂酸镁为润滑剂。
处方原料(规格:5mg):
托拉塞米5g;
甘露醇56g;
乳糖17.8g;
胶态二氧化硅0.8g;
硬脂酸镁0.4g;
制备1000片。
1、将托拉塞米粉碎处理,粒径D90≦90μm;
2、按将甘露醇、乳糖过40目筛,与托拉塞米在混料机中混合20min,速度150rpm;
3、将平均粒径120nm的胶态二氧化硅加入混料机,混合10min,速度150rpm;
4、将平均粒径6.5μm的片状晶体硬脂酸镁加入混料机,混合10min,速度100rpm,温度32℃;
5、混合后的物料压片温度30℃,压片时间50s压片即得。
实施例2:
处方原料(规格:5mg):
托拉塞米5g;
甘露醇88g;
乳糖45g;
胶态二氧化硅1.2g;
硬脂酸镁0.8g;
制备1000片。
1、将托拉塞米过经过粉碎和筛选处理,保证托拉塞米粉末的粒径D90≦120μm;
2、将甘露醇和乳糖分别经过30目筛子后,与托拉塞米粉末在混料机中混合25min,搅拌速度220rpm;
3、将平均粒径为100nm纳米硅溶胶的胶态二氧化硅加入混料机中混合15min,搅拌速度180rpm;
4、将平均粒径为5.5μm的片状晶体形状的硬脂酸镁加入混料机中混合15min,搅拌速度90rpm,控制温度30℃;
5、将混合后的处方原料转入压片模具,控制压片温度30℃,压片时间30s进行制片得到托拉塞米片。
实施例3:
处方原料(规格:10mg):
托拉塞米10g;
甘露醇112g;
乳糖35.6g;
胶态二氧化硅1.6g;
硬脂酸镁0.8g;
制备1000片。
1、将托拉塞米粉碎处理,粒径D90≦70μm;
2、按将甘露醇、乳糖过35目筛,与托拉塞米在混料机中混合25min,速度180rpm;
3、将平均粒径80nm的胶态二氧化硅加入混料机,混合18min,速度130rpm;
4、将平均粒径5.5μm的片状晶体硬脂酸镁加入混料机混合18min,速度80rpm,温度31℃;
5、混合后的物料压片温度29℃,压片时间55s压片即得。
实施例4:
处方原料(规格:10mg):
托拉塞米10g;
甘露醇172g;
乳糖74g;
胶态二氧化硅2.4g;
硬脂酸镁1.6g;
制备1000片。
1、将托拉塞米过经过粉碎和筛选处理,保证托拉塞米粉末的粒径D90≦140μm;
2、将甘露醇和乳糖分别经过35目筛子后,与托拉塞米粉末在混料机中混合30min,搅拌速度200rpm;
3、将平均粒径为140nm纳米硅溶胶的胶态二氧化硅加入混料机中混合18min,搅拌速度160rpm;
4、将平均粒径为4.5μm的片状晶体形状的硬脂酸镁加入混料机中混合18min,搅拌速度110rpm,控制温度31.5℃;
5、将混合后的处方原料转入压片模具,控制压片温度29.℃,压片时间40s进行制片得到托拉塞米片。
实施例5:
处方原料(规格:20mg):
托拉塞米20g;
甘露醇224g;
乳糖71.2g;
胶态二氧化硅3.2g;
硬脂酸镁1.6g;
制备1000片。
1、将托拉塞米粉碎处理,粒径D90≦100μm;
2、按将甘露醇、乳糖过40目筛,与托拉塞米在混料机中混合20min,速度150rpm;
3、将平均粒径110nm的胶态二氧化硅加入混料机,混合10min,速度150rpm;
4、将平均粒径5.5μm的片状晶体硬脂酸镁加入混料机,混合10min,速度100rpm,温度32℃;
5、混合后的物料压片温度30℃,压片时间50s压片即得。
实施例6:
处方原料(规格:20mg):
托拉塞米20g;
甘露醇239g;
乳糖95g;
胶态二氧化硅3.6g;
硬脂酸镁2.4g;
制备1000片。
1、将托拉塞米过经过粉碎和筛选处理,保证托拉塞米粉末的粒径D90≦80μm;
2、将甘露醇和乳糖分别经过30目筛子后,与托拉塞米粉末在混料机中混合30min,搅拌速度220rpm;
3、将平均粒径为60nm纳米硅溶胶的胶态二氧化硅加入混料机中混合18min,搅拌速度160rpm;
4、将平均粒径为5.5μm的片状晶体形状的硬脂酸镁加入混料机中混合15min,搅拌速度120rpm,控制温度30.5℃;
5、将混合后的处方原料转入压片模具,控制压片温度28.5℃,压片时间45s进行制片得到托拉塞米片。
经过上述制备方法得到的托拉塞米片,与某市售制剂片的含量、溶出度、稳定性进行对比检测,性能参见表格1和表格2。
表格1托拉塞米片含量和溶出度对比检测结果
药品 | 含量 | 溶出度(0.1M盐酸介质,30min) |
实施例1 | 99.7% | 99.3% |
实施例2 | 99.6% | 99.4% |
实施例3 | 100.7% | 99.9% |
实施例4 | 100.8% | 99.8% |
实施例5 | 99.9% | 99.7% |
实施例6 | 99.8% | 99.7% |
某市售制剂-5mg片 | 100.3% | 100.5% |
表格2托拉塞米片稳定性对比检测结果
从表格1和表格2中可以看出,选择较小粒径的片状晶体形状的硬脂酸镁作为润滑剂,纳米硅溶胶式胶态二氧化硅作为助流剂,得到的托拉塞米片药品稳定性好;通过选择性控制托拉塞米粉末的粒径为D90≦150μm,在药物服用时易于溶解,且持续平稳溶出,提高药品的有效性和持续作用时间;实现零级释放、平稳溶出、降压平稳,患患者口服后能充分吸收。
需要指出的是,上述较佳实施例仅为说明本发明的技术构思及特点,其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施,并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰,都应涵盖在本发明的保护范围之内。
Claims (7)
1.一种托拉塞米片,其特征在于,处方原料组分包括:托拉塞米1~20份,甘露醇50~250份,乳糖5~100份,胶态二氧化硅0.25~4份,硬脂酸镁0.25~2.5份。
2.根据权利要求1所述托拉塞米片,其特征在于:所述托拉塞米的粉末平均粒径D90≦150μm。
3.根据权利要求1所述托拉塞米片,其特征在于:所述硬脂酸镁为平均粒径为3.5~7μm的片状晶体。
4.根据权利要求1所述托拉塞米片,其特征在于:所述胶态二氧化硅为纳米硅溶胶,平均粒径为50~150nm。
5.根据权利要求1所述托拉塞米片,其特征在于:所述甘露醇和乳糖分别经过30~40目筛子过筛而得。
6.根据权利要求1~5任一项所述一种托拉塞米片的制备方法,其特征在于,包括以下步骤:
S1处方原料处理,将托拉塞米粗品过经过粉碎和筛选处理;
S2填充剂混合,将甘露醇和乳糖与托拉塞米粉末在混料机中混合20min~30min,搅拌速度150~250rpm;
S3助留处理,将胶态二氧化硅加入混料机中混合10min~20min,搅拌速度100~200rpm;
S4润滑处理,将硬脂酸镁加入混料机中混合10min~20min,搅拌速度80~120rpm,控制处方原料温度30~32℃;
S5制片,将混合后的处方原料转入压片模具进行制片得到托拉塞米片。
7.根据权利要求6所述托拉塞米片的制备方法,其特征在于:步骤S5所述制片的压片温度28~30℃,压片时间30~60s。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111264676.8A CN113750068A (zh) | 2021-10-28 | 2021-10-28 | 一种托拉塞米片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111264676.8A CN113750068A (zh) | 2021-10-28 | 2021-10-28 | 一种托拉塞米片及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113750068A true CN113750068A (zh) | 2021-12-07 |
Family
ID=78784553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111264676.8A Pending CN113750068A (zh) | 2021-10-28 | 2021-10-28 | 一种托拉塞米片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113750068A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050169991A1 (en) * | 2003-12-12 | 2005-08-04 | Penwest Pharmaceuticals Co. | Sustained release torsemide dosage forms |
CN105949115A (zh) * | 2016-05-26 | 2016-09-21 | 南京正科医药股份有限公司 | 一种新晶型托拉塞米 |
CN106038500A (zh) * | 2016-05-26 | 2016-10-26 | 南京正科医药股份有限公司 | 一种托拉塞米片 |
-
2021
- 2021-10-28 CN CN202111264676.8A patent/CN113750068A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050169991A1 (en) * | 2003-12-12 | 2005-08-04 | Penwest Pharmaceuticals Co. | Sustained release torsemide dosage forms |
CN105949115A (zh) * | 2016-05-26 | 2016-09-21 | 南京正科医药股份有限公司 | 一种新晶型托拉塞米 |
CN106038500A (zh) * | 2016-05-26 | 2016-10-26 | 南京正科医药股份有限公司 | 一种托拉塞米片 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101780073B (zh) | 非布司他分散片药物及其制备方法 | |
WO2020249001A1 (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
WO2010085014A1 (en) | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same | |
WO2011160541A1 (zh) | 托伐普坦固体分散体及其制备方法 | |
CN105496977A (zh) | 琥珀酸曲格列汀口崩片及其制备方法 | |
CN103239419A (zh) | 茶碱缓释片的制备方法 | |
CN113041250B (zh) | 一种缬沙坦氢氯噻嗪复方制剂及其制备工艺 | |
CN113750068A (zh) | 一种托拉塞米片及其制备方法 | |
CN104644594A (zh) | 一种氢溴酸沃替西汀胃溶片及其制备方法 | |
CN106619572A (zh) | 一种喹烯酮缓释微丸及其制备方法 | |
CN101797250A (zh) | 一种稳定的复方制剂 | |
CN111388439B (zh) | 一种含有甲磺酸多沙唑嗪速释与缓释的片剂及其制备方法 | |
CN107982235A (zh) | 一种吲达帕胺片及其制备方法 | |
CN110898021A (zh) | 一种厄贝沙坦氢氯噻嗪的复合制剂及其制备方法 | |
CN113143880A (zh) | 一种治疗糖尿病并发症的缓释片及其制备方法 | |
CN112641743A (zh) | 一种用于治疗高血压的复方制剂及其制备工艺 | |
CN106606496A (zh) | 萘普生和埃索美拉唑镁复方肠溶片及其制备方法 | |
CN105106144A (zh) | 一种盐酸西那卡塞固体分散体片剂及其制备工艺 | |
CN110115715A (zh) | 一种含厄贝沙坦的复方片剂及其制备方法 | |
CN108853044A (zh) | 一种硝苯地平缓释片及其制备方法 | |
CN103585151B (zh) | 一种法莫替丁和右旋布洛芬复方片剂及其制备方法 | |
CN114504559B (zh) | 一种药用辅料乳糖纤维素共处理物的制备方法 | |
CN106466302A (zh) | 口服氯化钾缓释片及其制备方法 | |
CN106491550B (zh) | 一种含有喹硫平或其药学上可接受的盐的缓释片及其制备方法 | |
CN102327277B (zh) | 一种福辛普利钠氢氯噻嗪药用组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211207 |